Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818471 | 0.93 | CYP11B2 (0.38) | GPR55CYP11B2KMOKCNJ1CREBBP | |
| SCHEMBL473830 | 0.92 | KMO (0.35) | GPR55CYP11B2KMOPKMGFER | |
| SCHEMBL12164176 | 0.92 | KMO (0.35) | GPR55CYP11B2KMOPKMGFER | |
| SCHEMBL12164222 | 0.88 | CYP11B2 (0.42) | GPR55CYP11B2KMOKCNJ1CREBBP | |
| SCHEMBL12164103 | 0.88 | GPR55 (0.36) | GPR55CYP11B2KMOKCNJ1 | |
| SCHEMBL473836 | 0.88 | GPR55 (0.36) | GPR55CYP11B2KMOKCNJ1 | |
| SCHEMBL473819 | 0.88 | CYP11B2 (0.42) | GPR55CYP11B2KMOKCNJ1CREBBP | |
| SCHEMBL473909 | 0.87 | GPR55 (0.40) | GPR55CYP11B2KMOKCNJ1CREBBP | |
| SCHEMBL12164224 | 0.87 | GPR55 (0.40) | GPR55CYP11B2KMOKCNJ1CREBBP | |
| SCHEMBL473935 | 0.87 | KMO (0.35) | GPR55CYP11B2KMOPKMGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249124-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249124-A1 | 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, MC2R | GPR55 258/4885CYP11B2 10/4885KMO 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.